Accelerator Mass Spectrometry

Pharmaron is the recognized leader in the use of Accelerator Mass Spectrometry (AMS) technology (NEC 250 KeV Single Stage AMS). The AMS team is primarily focused on pharmaceutical and biopharmaceutical R&D, employing AMS as a unique, ultra-sensitive ¹⁴C analytical tool to support clinical and preclinical studies, primarily related to metabolism, distribution and bioanalysis (ADME/PK). In addition to the typical AMS study designs below, Pharmaron can also employ AMS to deliver unique solutions and deconvolute complex specific compound-related questions.

AMS Advantages:

A wide range of sample types can be analyzed
- Standard matrices e.g. plasma, whole blood, urine, feces etc.
- More unusual matrices e.g. bile, expired air traps, dialysate, tissue
  (tumor biopsies), CSF
Matrix interference does not impact on the result
Highly sensitive: 1-2 pg/mL for specific analyte quantification is routine, can go much lower

Capabilities

Carbon-14 Microtracers

Ultra-sensitive AMS

Accelerated Carbon-14 Clinical Programs

Phase 0 Microdosing

Absolute Bioavailability and IV Pharmacokinetics

Mass Balance by AMS

Metabolite Profiling Using AMS

AMS for Carbon-14 Non-clinical Studies

Carbon-14 Radiolabels and AMS for Biologics

Mass balance and total [¹⁴C] by AMS (total radioactivity levels in blood, plasma, excreta)
Metabolite profiling by HPLC/UPLC fractionation combined with quantitation of radio-profiles by AMS
Absolute bioavailability (IVPK) – IV ¹⁴C-microtracer and PK analysis of the “hot” IV dose utilizing a fully validated LC-AMS bioanalytical assay for ¹⁴C-parent (and/or ¹⁴C-metabolites)
¹⁴C dose solution analysis for very low specific activity ¹⁴C dose preparations